Bonac Co., a Fukuoka-based startup with a focus on RNA therapeutics, has entered into an agreement with Toray to license for domestic use its drug candidate BNC-1021, an RNA for the treatment of idiopathic pulmonary fibrosis, to Toray who in turn has bought new Bonac shares.
Toray news release, January 6, 2016
Toray obtains domestic rights for RNA therapeutic for idiopathic fibrosis from Bonac